BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase II
AstraZeneca PLC (AZN) Pops On Possibility Of Another Pfizer Inc. (PFE) Bid; Start Of New Cancer Trial 8/29/2014
Dezima Pharma Reports Positive Results In Its Phase 2b TULIP Trial With CETP Inhibitor TA-8995 In Dyslipidemia 8/29/2014
Repros Therapeutics Inc. (RPRX)'s Testosterone Drug Found Superior To AbbVie (ABBV)'s Androgel In Study 8/28/2014
Pfizer Inc. (PFE)’s Investigational Vaccine Candidate For Clostridium Difficile Receives FDA Fast Track Designation 8/28/2014
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce Initiation Of Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema 8/28/2014
Madison Vaccines To Be Used In Clinical Trial Of A New Combination Approach To Immunotherapy Funded By The Prostate Cancer Foundation And The Movember Foundation 8/28/2014
Auxilium Pharmaceuticals (AUXL) To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 8/28/2014
Gilead Sciences, Inc. (GILD) Shaky As Achillion Pharmaceuticals, Inc. (ACHN)'s Hepatitis C Drug Cures All Patients In Mid-Stage Trial 8/27/2014
Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury 8/27/2014
ERYtech Pharma Announces Second Positive DSMB Review Of Its Phase 2b Study In Acute Myeloid Leukemia 8/27/2014
AVANIR Pharmaceuticals (AVNR) Announces Initiation Of Phase 2 Study Of AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 8/26/2014
Ruthigen Receives Recommendation From Data Monitoring Committee To Initiate Phase 1/2 Human Clinical Trial Of RUT58-60 8/26/2014
Profil Institute for Clinical Research, Inc. Reaches Milestone In Early Phase Clinical Research For Diabetes 8/26/2014
Anavex Life Sciences Corp. (AVXL.OB) Selects The Alfred Hospital In Melbourne, Australia As Lead Site For Phase 2a Alzheimer's Clinical Trial 8/26/2014
U.S. Army Funds Phase 2 Clinical Trial At University of California, Los Angeles (UCLA) For The Treatment Of PTSD With The NeuroSigma, Inc. eTNS System 8/25/2014
Pradaxa® (dabigatran etexilate mesylate) Data To Be Presented At European Society of Cardiology Congress 2014 8/25/2014
Auxilium Pharmaceuticals (AUXL) Drug Found Effective Against Cellulite In Phase 2 Study 8/22/2014
Look Out Auxilium Pharmaceuticals (AUXL), BioSpecifics Technologies Corporation (BSTC) Also Touts Positive Data From Phase 2a Study Of CCH For Cellulite 8/22/2014
NovaBay Pharmaceuticals, Inc. (NBY) Reports NVC-422 Missed Endpoints In Phase 2 Study 8/21/2014
Boston Therapeutics, Inc. Completes Enrollment Of Patients With Type 2 Diabetes In Phase IIb Study On BTI-320 In The U.S. 8/20/2014
Cellceutix (CTIX) Completes Enrollment In Phase 2b Clinical Trial Of Brilacidin For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) 8/19/2014
MediciNova, Inc. Shows Off Positive Phase 2a Study Of Ibudilast 8/19/2014
iCo Therapeutics Inc. Announces Positive Oral Amphotericin B Study Results 8/19/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Fragile X Syndrome 8/19/2014
Celator Pharmaceuticals, Inc. Initiates Pharmacokinetic And Pharmacodynamics Clinical Study Of CPX-351 8/19/2014
DelMar Pharmaceuticals Provides Update On Glioblastoma Clinical Trial And Results Of Warrant Tender Offer 8/19/2014
Innate Immunotherapeutics’s Phase 2B Clinical Trial On SPMS To Start Recruiting Patients Following Perth Site Obtaining Ethics Approval 8/19/2014
Blanchette Rockefeller Neurosciences Institute Release: Human Brain Deficits Of PKCe: Targeted For Alzheimer's Disease Therapeutic And Diagnostic Trials 8/18/2014
Data Published By Researchers From The Scripps Research Institute Demonstrate Potential For MYC Inhibitor Licensed By Sorrento Therapeutics, Inc. 8/18/2014
Egalet Announces Successful End-Of-Phase 2 Meeting With The FDA For Egalet-002 8/18/2014
NeuroVive Pharmaceutical ABl: Enrollment To Phase 2 Study On NeuroSTAT® Continues 8/15/2014
Austrianova Release: Human Clinical Trials Confirm Safety And Efficacy Of Encapsulated Cell Treatment For Pancreatic Cancer 8/15/2014
Publication By KaloBios Pharmaceuticals, Inc. (KBIO) And Collaborators Shows EphA3 As Target For Highly Selective Anticancer Therapy 8/14/2014
Rigel Pharmaceuticals, Inc. (RIGL) Experimental Eye Drug R348 Fails Mid-Stage Study 8/14/2014
Ohr Pharmaceutical (OHRP) Announces Additional Squalamine Eye Drop (OHR-102) Phase 2 Clinical Data In Wet-AMD; The IMPACT Study 8/13/2014
Intercept Pharmaceuticals (ICPT) Soars As Liver Drug Found Effective In Mid-Stage Trial 8/13/2014
Cellular Biomedicine Group (CBMG) Completes Patient Treatment In Phase 2b Clinical Trial For Rejoin™ Therapy For Knee Osteoarthritis 8/12/2014
Juventas Therapeutics, Inc. Completes Enrollment Of Phase I/II RETRO-HF Trial And Demonstrates Safety For Retrograde Infusion Of JVS-100 In Patients With Heart Failure 8/12/2014
Esperion Therapeutics, Inc. (ESPR) Provides Etc-1002 Development Program Update; Reports Second Quarter 2014 Financial Results 8/12/2014
Biodel Inc. (BIOD)'s Insulin Drug Found Effective In Phase 2 Trial 8/11/2014
Ohr Pharmaceutical (OHRP) Announces Squalamine Eye Drop (OHR-102) Phase 2 Clinical Data in Retinal Vein Occlusion 8/11/2014
Concordia Healthcare Corp (CXR.TO) Announces First Patients Enrolled In Phase 2 Clinical Trial Using Photodynamic Therapy With PHOTOFRIN(R) For Patients With Mesothelioma 8/11/2014
Mirati Therapeutics  (MRTX) Receives Orphan Designation From U.S. FDA For Mocetinostat In Diffuse Large B-Cell Lymphoma 8/11/2014
Celladon Corporation Announces Trial To Investigate MYDICAR In Patients With Heart Failure And LVAD 8/11/2014
Xenetic Biosciences Announces Ongoing Safety And Efficacy Data From Phase 2 Trial Of Erepoxen(R) 8/11/2014
BioSpecifics Technologies Corporation (BSTC) Announces Initiation Of Phase 2 Clinical Study Of CCH For Treatment Of Lipoma 8/8/2014
Alcobra (ADHD) Releases New Neuroimaging Data Supporting Pro-Cognitive Effects Of MDX 8/8/2014
Oral Presentation Of CytRx Corporation (CYTR)’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology 8/7/2014
Symphogen A/S Release: Sym004 Advances Into Two New Clinical Trials And Receives Milestone Payments 8/7/2014
Neurovance Completes Enrollment In Human Abuse Liability Study For Centanafadine (Formerly Called EB-1020) For Adult ADHD 8/7/2014
San Diego's Cytori Therapeutics, Inc. (CYTX) Crashes As Safety Concerns Suspend Athena Trials 8/7/2014
Egalet Announces Topline Results From Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001 8/6/2014
Celsus Therapeutics (CLTX) Announces First Patient Enrolled In Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis 8/6/2014
Cara Therapeutics, Inc. (CARA) Initiates Proof-Of-Concept Phase 2 Trial Of I.V. CR845 In Uremic Pruritus 8/6/2014
Synthetic Biologics, Inc. (SYN) On Track To Initiate Clinical Program For SYN-004 To Protect Against C. difficile 8/5/2014
Atox Bio Release: AB103 Granted Orphan Medicinal Product Designation In The European Union For The Treatment Of Necrotizing Soft Tissue Infections (NSTI) 8/5/2014
Ophthotech Corporation (OPHT) Initiates First Of Several Expansion Studies To Further Evaluate Fovista® (Anti-PDGF) Therapy In Patients With Wet Age-Related Macular Degeneration 8/5/2014
Velocity Pharmaceutical Development, LLC And Tigercat Pharma, Inc. Announce First Patient Dosed In Phase 2 Study Of VPD-737 In Prurigo Nodularis 8/4/2014
Cellceutix (CTIX) Believes Brilacidin On Track To Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment In Phase 2b Trial For Acute Bacterial Skin And Skin Structure Infections Expected This Month 8/4/2014
Final Patient Treated In NeuralStem Inc. Phase II ALS Stem Cell Trial 8/4/2014
Amarantus BioSciences, Inc. Announces Positive Top-Line Interim Clinical Data For Alzheimer's Blood Diagnostic Lympro Test® 8/4/2014
Heat Biologics Amends Bladder Cancer Protocol For Early Advancement Into Phase 2 Clinical Studies 8/4/2014
NPS Pharmaceuticals, Inc. (NPSP) Initiates Phase 2a Study Of NPSP795 In Adult Patients With Autosomal Dominant Hypocalcemia (ADH) 8/4/2014
Novartis AG (NVS) Malaria Pill KAE609 Shows Promise As Best Drugs Fail 8/1/2014
Biota Pharmaceuticals, Inc. (BOTA) Stock Crashes As Influenza Drug Laninamivir Octanoate Fails Mid-Stage Trial; Stock Down -20.54% At 11:37AM ET 8/1/2014
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV 7/31/2014
Expanded Data On Disability And Cognitive Improvements In Phase 2 Study Of Synthetic Biologics, Inc. (SYN)' Trimesta™ In Multiple Sclerosis To Be Presented At 2014 Joint ACTRIMS-ECTRIMS Meeting 7/31/2014
NOXXON Pharma AG Initiates Phase IIa Study Of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) In Dialysis Patients With EPO-hyporesponsive Anemia 7/31/2014
Kala Pharmaceuticals Initiates Phase 2 Clinical Trial To Evaluate LE-MPP (KPI-121) In Patients With Retinal Vein Occlusion And Diabetic Macular Edema 7/31/2014
Immune Pharmaceuticals, Inc. Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 7/30/2014
RXi Pharmaceuticals (RXII) Expands Clinical Program With Initiation Of Third Phase 2a Study With RXI-109 For Treatment Of Hypertrophic Scars 7/30/2014
Amarantus BioSciences, Inc. Amends LymPro LP-002 Clinical Protocol to Report Interim Data at Presentation 7/30/2014
BioTie Therapies Corp. Updates Outlook On Tozadenant And SYN120 7/30/2014
EMD Serono Initiates Phase 2 Study Of Anti-PD-L1 Antibody MSB0010718C In Metastatic Merkel Cell Carcinoma 7/29/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Dosing Completed 7/29/2014
Neurotrope Initiates Phase 2a Study Of Bryostatin For The Treatment Of Alzheimer's Disease - Doses First Patients 7/29/2014
Quark Pharmaceuticals Inc. Reports Favorable Data From Phase 2 Clinical Trial Evaluating Investigational siRNA QPI-1002 7/29/2014
MorphoSys AG Provides Update On The Company's Proprietary Drug Portfolio 7/28/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Retroscreen Conducts Landmark hVIVO Human Challenge Model Study Of AL-8176 In RSV For Alios BioPharma 7/28/2014
Medivir AB (MVRBF): Phase II COSMOS Study Results Published In Lancet On World Hepatitis Day 7/28/2014
Phase 2 COSMOS Study Results Published In The Lancet Demonstrate Efficacy And Safety Of Janssen’s Once-Daily Simeprevir In All Oral 12-Week Combination With Sofosbuvir For Genotype 1 Chronic Hepatitis C 7/28/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase II Study Of ERY-ASP In Pancreatic Cancer 7/28/2014
Quark Pharmaceuticals Inc. Reports Favorable Results From Phase 2 Clinical Trial Evaluating Investigational Sirna QPI-1002 7/28/2014
Esperion Therapeutics, Inc. (ESPR) Announces Initiation Of A Phase 2 Clinical Study Of ETC-1002 In Patients With Hypercholesterolemia And Hypertension 7/24/2014
Alios BioPharma Reports Positive Results Of Its Anti-RSV Nucleoside Analog AL-8176 In A Phase 2 Challenge Study In Adults Infected With Respiratory Syncytial Virus (RSV) 7/24/2014
Celsion Corporation (CLSN) Announces Positive Interim Data Update From Its Phase 2 DIGNITY Study In Breast Cancer 7/24/2014
Innapharma: Completion Of Target Enrollment In The Phase 2 EffiKIR Trial 7/24/2014
Inovio Pharmaceuticals (INO) HPV Immunotherapy Achieves Primary Efficacy Endpoint In Randomized Phase 2 Cervical Dysplasia Trial 7/23/2014
Aduro Biotech Receives Breakthrough Therapy Designation From FDA For Innovative Pancreatic Cancer Combination Immunotherapy 7/23/2014
Biotron Limited (BIT:AU) BIT225 Reverses HIV-Induced Impairment Of The Immune System 7/23/2014
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus 7/22/2014
Advaxis, Inc. And MedImmune (AZN) Partner On Immuno-Oncology Combination Clinical Trial 7/22/2014
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014
Argos Therapeutics, Inc. (ARGS) Presents Data Showing The Impact Of HIV Antigen Sequence Divergence On Durable Viral Control Following Treatment With Autologous Immune Therapy 7/22/2014
Genocea Biosciences HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects 7/22/2014
Enrollment Commences In NeuroSigma, Inc.-Sponsored Pediatric Clinical Trial For The Treatment Of Lennox-Gastaut Syndrome 7/22/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase I/II Study Of ERY-ASP In Acute Lymphoblastic Leukemia In The United States 7/22/2014
Halozyme Therapeutics, Inc. (HALO) Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 7/22/2014
ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update 7/22/2014
Genocea Biosciences Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy 7/21/2014
CASI Pharmaceuticals  (ENMD) Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With Enmd-2076 For Triple-Negative Breast Cancer In China 7/21/2014
AVANIR Pharmaceuticals (AVNR) Announces FDA Acceptance Of IND For AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 7/21/2014
Anavex Life Sciences Corp. (AVXL.OB) Achieves Key Milestone As It Secures Cgmp Manufacturing For Drug Candidate Trial Supplies 7/21/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
CASI Pharmaceuticals  (ENMD) To Start China Trial Of Cancer Drug 7/21/2014
Amarantus BioSciences, Inc. Discusses New Independent Peer-Reviewed Research Papers On MANF 7/18/2014
Roche (RHHBY) Alzheimer's Drug Crenezumab Fails Main Goals In Phase 2 Study 7/17/2014
Consortium Of Food Allergy Research Completes Recruitment Of National Institutes of Health (NIH)-Sponsored Cofar6 Phase 2Trial With DBV Technologies's Viaskin® Peanut In Treatment Of Peanut Allergy 7/17/2014
Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial For SD-809 In Tardive Dyskinesia 7/17/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 2 Study Of ISIS-APO(a) Rx In Patients With High Lp(a) 7/17/2014
DBV Technologies Completes Last "Food Challenge" Visit Of Last Peanut-Allergic Patient In VIPES Phase 2b Clinical Study 7/17/2014
Synergy Pharmaceuticals Completes Patient Enrollment For Its SP-333 Phase 2 Trial In Patients With Opioid-Induced Constipation 7/17/2014
Juvenile Diabetes Research Foundation Partner ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Key Project Milestone To Advance Innovative Encapsulated Cell Replacement Therapy Product For Type 1 Diabetes 7/17/2014
Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60 7/17/2014
Targacept, Inc. (TRGT) Stops Alzheimer's Drug Trial After It Fails Phase 2b Trial 7/16/2014
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer 7/16/2014
Adynxx Initiates Phase 2 Dose-Ranging Study Of AYX1, Lead Compound For The Prevention Of Post-Surgical Pain 7/16/2014
Resolve Therapeutics Initiates Phase 2 Clinical Study In SLE 7/16/2014
BioTie Therapies Corp. Selects Bracket's CDR System™ For Phase 2 Trial Of Treatment Of Parkinson's Disease 7/16/2014
GenSpera Presents G-202 HCC Clinical Trial Update At 5th Asia-Pacific Primary Liver Cancer Expert Meeting 7/15/2014
Amarantus BioSciences, Inc. Announces Positive Clinical Performance And 7-Year Longitudinal Data Poster Presentations For Lympro Test® At AAIC 2014 7/15/2014
CellAct Pharma Receives Orphan Drug Designation In EU For CAP7.1 In Biliary Tract Cancers 7/15/2014
Amarillo Biosciences (AMAR) Announces Positive Analytical Performance Data Poster Presentation For Lympro Test At AAIC 2014 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Study Of VT-1161 In Patients With Moderate To Severe Acute Vulvovaginal Candidiasis 7/11/2014
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Studies Of VT-1161 With Moderate To Severe Interdigital Tinea Pedis 7/11/2014
Genticel’s Phase 2 Study With ProCervix Passes The Halfway Mark For Patient Recruitment 7/10/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Tames Eczema In Phase 2b Trial 7/10/2014
Cytokinetics, Inc. (CYTK) Announced Additional Results Relating To Tirasemtiv From Pre-Specificed Subgroup Analyses Of BENEFIT-ALS 7/10/2014
Zafgen (ZFGN) Granted Orphan Drug Designation In The European Union For Beloranib, A First-In-Class Metap2 Inhibitor For The Treatment Of Prader-Willi Syndrome 7/10/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
SillaJen Lead Product Pexa-Vec Featured In "Nature Reviews Cancer" Article Summarizing The Potential Of Oncolytic Immunotherapy 7/10/2014
Latest Sarepta Therapeutics (SRPT) Phase 2 Data Shows Greater Decline in Walking Ability For Muscular Dystrophy Patients 7/10/2014
Boehringer Ingelheim Corporation's Breakthrough Cancer Drug Volasertib Effective In Phase 2 Trial 7/9/2014
National Institutes of Health (NIH) Funds Phase 2 Clinical Trial At University of California, Los Angeles (UCLA) For The Treatment Of ADHD With NeuroSigma, Inc.'s eTNS Systemnational 7/9/2014
Acasti Pharma Completes Phase 2 Double Blind (TRIFECTA) And Pharmacokinetic Trials 7/9/2014
Adocia Announces Approval To Start A Phase IIa Clinical Study Of Hinsbet®, Its Fast-Acting Human Insulin, In Type 1 Diabetes 7/9/2014
Lexicon Pharmaceuticals, Inc. (LXRX) And Juvenile Diabetes Research Foundation Collaborate For Phase 2 Clinical Trial Of LX4211 In Type 1 Diabetes 7/9/2014
480 Biomedical Awarded $1 Million Phase II NHLBI Contract To Advance Bioresorbable Scaffold For Pediatric Pulmonary Artery Stenosis 7/9/2014
Opko Health, Inc.'s Long-Acting Clotting Factor VIIa-CTP Receives Positive Opinion For Three Orphan Drug Designations In Europe 7/9/2014
NeoStem, Inc. Presents Five-Year Survival Data For Autologous Melanoma Immunotherapy Targeting Cancer Stem Cells At American Society of Clinical Oncology Annual Meeting 7/9/2014
Pluristem Therapeutics (PSTI) Initiates South Korean Arm of Multinational Phase 2 Intermittent Claudication Trial 7/8/2014
PRC Clinical Completes Over 800 Monitoring Visits In Global Phase 2b Neurology Study 7/8/2014
BioTie Therapies Corp.: Tozadenant Phase 2b Parkinson's Disease Study Published In Lancet Neurology 7/8/2014
Avraham Pharmaceuticals Ltd. Announces Successful Interim Results In Phase 2b Study Of Ladostigil For The Treatment Of MCI 7/8/2014
CardioCell Begins Phase IIa Clinical Trial Using itMSC Therapy To Treat Chronic Heart Failure (HF) Due To Non-Ischemic Cardiomyopathy 7/8/2014
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Patient Enrollment IN U.S. Randomized Phase 2 Pancreatic Cancer Study 7/8/2014
Synergy Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For Plecanatide In Irritable Bowel Syndrome With Constipation 7/8/2014
Dignity Sciences Release: DS107E-02 - Positive Phase 2 Results In Atopic Dermatitis 7/8/2014
Celladon Corporation Announces New Clinical Development Initiatives For MYDICAR® 7/7/2014
CASI Pharmaceuticals  (ENMD) Receives U.S. Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma 7/7/2014
GenSpera To Present Ongoing HCC Trial Data At APPLE 2014 Congress July 12th In Taipei 7/7/2014
Amgen (AMGN) Wins FDA Breakthrough Therapy Designation For Investigational BiTE 7/3/2014
Quark Pharmaceuticals Inc. Announces Completion Of Phase 2 Trial Evaluating QPI-1002 For Prevention Of Delayed Graft Function In Kidney Transplant Patients 7/1/2014
Ultragenyx Pharmaceuticals (RARE) Announces Initiation Of A Phase 2 Study Of KRN23 For Pediatric X-Linked Hypophosphatemia In The US And EU 7/1/2014
AVANIR Pharmaceuticals (AVNR) Announces Two Data Presentations Related To Pseudobulbar Affect (PBA) At The Alzheimer's Association International Conference (AAIC) 7/1/2014
Agenus (AGEN) Brain Cancer Vaccine Shows Extended Survival In Phase 2 Final Data Analysis 7/1/2014
Threshold Pharmaceuticals, Inc. (THLD) Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial Of TH-302 In Combination With Pemetrexed In Advanced Non-Squamous Non-Small Cell Lung Cancer 7/1/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment 7/1/2014
Molecular Partners AG Release: Stage 3 Phase 2 Study Of DARPin Abicipar Pegol (Previously MP0112) Supports Progressing To Phase 3 Development Program 7/1/2014
Agenus (AGEN)'s Brain Cancer Vaccine Doubles Survival Rate In Phase 2 Study 7/1/2014
Aclaris Therapeutics Announces Positive Results From Phase 2 Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Skin Tumor 6/30/2014
Ampio Pharmaceuticals, Inc. (AMPE) Initiates Study of Multiple Injections Of Ampion™ Into The Knees Of Patients With OA Of The Knee To Assess Its Healing And Cartilage Regeneration Effects 6/30/2014
Mologen AG (MOLGF.PK): Cancer Immune Therapy MGN1703 Shows Outstanding Long-Term Responses 6/30/2014
TiGenix Announces The Clinical Development Of Cx611 In Early Rheumatoid Arthritis And Severe Sepsis 6/30/2014
Aclaris Therapeutics Announces Positive Results From Phase 2 Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Skin Tumor 6/30/2014
Genervon Announces Biomarker Data From GALS-001 Clinical Trial For ALS 6/30/2014
Northwestern Medicine Release: Researchers Seek to Tackle Transplant Tolerance Using Patients' Own T Cells 6/30/2014
Amunix, Inc. Congratulates Versartis, Inc. (VSAR) On Its Positive Phase 2a Results With VRS-317 6/30/2014
Burzynski Research Institute Announces Presentations At The 16th International Symposium On Pediatric Neuro-Oncology 6/27/2014
Bellerophon Therapeutics Completes Enrollment Of Its Phase 2 Trial Of Inopulse® For Treatment Of Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) 6/27/2014
Coronado Biosciences (CNDO) Reports Topline Results From Investigator Initiated Pilot Study Of TSO In Adults With Autism Spectrum Disorder 6/26/2014
Alder Biopharmaceuticals Inc. Release: Data From Proof-Of-Concept Clinical Trial Of ALD403, A Monoclonal Antibody Against CGRP For The Prevention Of Migraine, To Be Presented At 56th Annual Scientific Meeting Of The American Headache Society 6/26/2014
Aurinia (ISA.TO) Initiates Phase 2b Clinical Trial Of Voclosporin To Treat Lupus Nephritis 6/26/2014
Nora Pharma Announces Initiation Of Phase 2 RESPONSE Research Study 6/26/2014
Basilea Pharmaceutica (BSLN.SW) Announces Start Of Phase 2a Study With Oncology Drug Candidate BAL101553 6/26/2014
Agenus (AGEN) Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation 6/26/2014
Ischemix Enrolls First Patient In Phase 2a Trial To Prevent Contrast-Induced Acute Kidney Injury 6/26/2014
Massachusetts' Agenus (AGEN) Touts Positive Phase 2 Data From HerpV Study 6/26/2014
Aerie Pharmaceuticals, Inc. (AERI) Soars As Combo Eye Drug Roclatan Performs Well In Phase 2b Trial; Stock Up +28.29% At Market Close (June 25, 2014) 6/26/2014
Antares Pharma, Inc. (ATRS) Release: Rapid Restoration And Consistent Maintenance Of Steady Blood Levels Achieved With Once-Weekly Subcutaneous Administration Of Testosterone Delivered With A Novel Auto Injector 6/25/2014
Synthetic Biologics, Inc. (SYN) Reports That Licensor Cedars-Sinai Medical Center Finds Eradication Of Gut Methane Improves Insulin Sensitivity And Lipid Profiles In Study Of Pre-Diabetic, Obese Patients 6/25/2014
NeuralStem Inc.'s NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder 6/25/2014
GenSpera Releases 2014 Biotechnology Industry Organization (BIO) International Presentation And HCC Clinical Trial Update For G-202 6/25/2014
NovaBiotics Ltd Release: Initiation Of A Phase IIa Clinical Study For Lynovex® In Cystic Fibrosis 6/25/2014
Quark Pharmaceuticals Inc. Announces First Patient Dosed In A Phase 2a Trial Evaluating QPI-1007 For Neuroprotection In Patients With Acute Primary Angle Closure Glaucoma 6/25/2014
Ohr Pharmaceutical (OHRP) To Host Conference Call And Webcast To Discuss Squalamine Interim Phase 2 Data In Wet-AMD 6/24/2014
Ohr Pharmaceutical (OHRP) Eye Drug Falls Short In Phase 2 Trial 6/24/2014
Versartis, Inc. (VSAR) Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results 6/24/2014
Karyopharm Therapeutics (KPTI) Initiates Registration-Directed, Randomized Study Of Selinexor (KPT-330) In Older Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) 6/24/2014
Actinium Pharmaceuticals, Inc. (ATNM.OB)’s Actimab-A And Alpha-Particle Immunotherapy Platform Further Validated At Society For Nuclear Medicine Annual Meeting 6/24/2014
EnGeneIC Pty Ltd Unveils Clinical Development Strategy for EDV™ Nanocell Technology 6/24/2014
XenoPort, Inc. (XNPT) Announces Initiation Of A Phase 2 Clinical Trial Of XP23829 In Patients With Psoriasis 6/23/2014
Genocea Biosciences Announces Positive Top-Line Phase 1 Results For Novel Universal Pneumococcus Vaccine Candidate GEN-004 6/23/2014
IP Group Plc – Portfolio Company Diurnal Reports Positive Phase 2 Results 6/23/2014
The European Medicines Agency And FDA Grant Orphan Drug Designation To PHARNEXT's PXT-3003 For The Treatment Of Charcot-Marie-Tooth Disease Type 1A 6/23/2014
Inovio Pharmaceuticals (INO) Initiates Cervical Cancer Clinical Trial 6/23/2014
Velocity Pharmaceutical Development, LLC And Tigercat Pharma, Inc. Announce Regulatory Clearance For Initiating Phase Ii Study With Vpd-737 In Prurigo Nodularis 6/23/2014